Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

NCT02767596 · Terminated

Last updated 2026-05-28

This clinical trial is testing the medication lixisenatide in adults with type 2 diabetes who have not responded well to other similar diabetes drugs.

Status Terminated Stopped early and will not restart.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 2 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-07 · est. completion 2017-02

Where 1 site · Israel

What this study is testing ClinicalTrials.gov NCT02767596 ↗

Description as written by the study sponsor.

The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting GLP-1 analog. Patients who fail to achieve significant improvement in diabetes control on basal insulin and Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The primary outcomes will be changes in HBA1C and weight.

Treatments tested

Lixisenatide also known as Lyxumia Drug
Basal insulins also known as Glargine, Detemir, Degludec Drug

patients are on basal insulin treatment

Main thing measured	Change in hemoglobin A1c
Sponsor	Laniado Hospital
Conditions studied	Diabetes Mellitus Type 2
GLP-1 drugs	lixisenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02767596 ↗